EIB Boosts Fresenius' €400M Expansion for Affordable EU Healthcare
The European Investment Bank (EIB) has shown strong support for the health and life sciences sector, providing over €22 billion in financing over the last five years. Recently, it has loaned €400 million to Fresenius, a leading healthcare group, to boost the availability of innovative medicines and biosimilars across Europe.
Fresenius, which has invested over €1 billion in European manufacturing over the last five years, will use this loan to expand its R&D activities and manufacturing of medical products and biosimilars. This aligns with its FutureFresenius agenda, aiming to strengthen pharmaceutical production resilience in the EU and facilitate access to modern and affordable healthcare.
The loan demonstrates the EIB's commitment to high-quality and affordable healthcare. Sara Hennicken, CFO of Fresenius, welcomed the loan as a valued recognition of the company's contribution to a healthy European future. Nicola Beer, Vice President of the EIB, highlighted the partnership's goal of delivering innovative, affordable solutions for millions of patients while strengthening the EU's resilience in medicine supply and research excellence.
The €400 million loan from the EIB to Fresenius is expected to enhance Europe's access to modern, affordable healthcare. It will support Fresenius' expansion of R&D activities and manufacturing, contributing to the EU's pharmaceutical production resilience. This investment is part of the EIB's broader commitment to the health and life sciences sector, having provided over €22 billion in financing over the last five years.
Read also:
- Delaware's Multilingual Learners Surge to 13%, Outpacing Funding and Teacher Support
- Hesse Delegation Heads to Finland to Learn from Immigration Integration Success
- Hessian Minister Leads Delegation to Finland for Labor Market Exchange
- Rüsselsheim: Affordable Housing Boom Ahead as City Attracts Residents and Investors
